Loading...
01/11 03:34
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call revealed mixed signals: strong revenue growth and reduced losses, but ongoing financial challenges and competitive pressures. The Q&A highlighted positive feedback on products and expansion efforts but also showed management's reluctance to provide clear guidance, raising concerns. The private placement and preferred share exchange offer could dilute stock value. Overall, the company's strategic initiatives and product performance are promising, but financial uncertainties and competitive challenges temper the outlook, resulting in a neutral sentiment.
Net Sales $9.2 million, a 42% increase compared to Q1 2024 and an 11% sequential gain over Q4 2024. This growth is attributed to the adoption of TriNav in new accounts, increased utilization of existing accounts, and the expansion of the salesforce.
Gross Margin 84%, slightly down from 85% in Q1 2024. The decrease is attributed to decreased factory volumes associated with a factory clean room expansion.
R&D Expenses $3.3 million, a decrease of 44% from Q1 2024. The reduction is due to the completion of nelitolimod patient enrollment in all PERIO studies.
General and Administrative Expenses $5 million, an increase of over 7% compared to Q4 2024, primarily due to the timing of audit and legal expenses.
Operating Losses $7.3 million, compared to losses of $11.7 million in Q1 2024. The decrease in losses is attributed to increased sales and reduced R&D expenses.
Adjusted EBITDA Losses $5.5 million, compared to losses of $10.4 million in Q1 2024. The decrease is primarily due to increased sales, reduced R&D expenses, and higher non-cash stock compensation expense.
Cash and Cash Equivalents $13 million at quarter end, with an additional $22 million raised in gross proceeds from a private placement after the quarter.
Net Sales: $9.2 million in net sales, a 42% increase compared to Q1 2024.
New Product Launches: Launched TriNav Large and TriGuide, expanding PEDD into larger vessels.
TriNav Flex Launch: Initiating full launch of TriNav Flex, designed for torturous vascular anatomy.
Market Share: Increased market share to 10% of liver, taste, and care procedures.
Unique Ordering Accounts: Increased unique ordering counts by 39% versus Q1 2024, adding 32 new accounts.
Reimbursement Expansion: CMS issued a HCPCS code, C8004, providing coverage for mapping procedures using TriNav.
Gross Margin: Gross margin of 84%, slightly down from 85% in Q1 2024 due to factory volume decrease.
R&D Expenses: R&D expenses totaled $3.3 million, a decrease of 44% from Q1 2024.
Operating Losses: Operating losses of $7.3 million, improved from $11.7 million in Q1 2024.
Partnership Strategy: Shifting to a partnership-focused strategy for nelitolimod to eliminate development expenses.
Investment Focus: Investing in strategic areas to accelerate development of new clinical applications.
Earnings Expectations: TriSalus Life Sciences missed earnings expectations with a reported EPS of $-0.33, compared to expectations of $-0.20.
Macroeconomic Conditions: Management highlighted that forward-looking statements involve material risks and uncertainties, including the impact of macroeconomic conditions and global events that could cause actual results to differ from expectations.
Regulatory Issues: The company is navigating the complexities of reimbursement and regulatory approvals, which are critical for the adoption of their technology.
Supply Chain Challenges: There was a noted decrease in gross margin from 85% to 84%, attributed to decreased factory volumes associated with a factory clean room expansion.
R&D Expenses: The company anticipates a significant reduction in R&D spending, particularly in the second half of the year, which may impact future product development.
Market Competition: TriSalus is facing competitive pressures in the interventional oncology space, necessitating continuous innovation and market penetration efforts.
Financial Performance: Despite revenue growth, the company does not anticipate being EBITDA positive or cash flow positive in 2025, indicating ongoing financial challenges.
Strategic Initiatives: TriSalus is focusing on growing market share for TriNav in the liver embolization market, advancing its technology pipeline, exploring new applications for pressure-enabled drug delivery (PEDD), and preparing nelitolimod for pharmaceutical partnerships.
Key Milestones: Completion of Phase 1 trials for nelitolimod, shift to a partnership-focused strategy to eliminate development expenses, and strong momentum in the liver embolization market.
Product Innovation: Launch of TriNav Large and TriGuide, and upcoming full launch of TriNav Flex to enhance procedural opportunities.
Clinical Applications: Initiation of the PROTECT Registry to evaluate PEDD for patients with thyroid nodules or goiters.
Revenue Growth Guidance: TriSalus confirms guidance of at least 50% revenue growth for 2025.
EBITDA Outlook: The company does not anticipate being EBITDA positive or cash flow positive in 2025.
R&D Spend Reduction: Significant reduction in R&D spend expected in the second half of 2025, with no further spend anticipated in 2026.
Cash Position: Raised approximately $22 million in gross proceeds through a private placement to strengthen the balance sheet.
Private Placement: Raised approximately $22 million in gross proceeds through a private placement.
Preferred Share Exchange Offer: Reached agreement with 55% of preferred shareholders to implement an exchange offer, converting preferred shares to common stock.
The earnings call reveals solid financial management, with improved cash flow and reduced operating losses. The company's commitment to a 50% growth target and strategic investments in new applications and products support a positive outlook. Despite management's reluctance to provide 2026 guidance, the market strategy and product development updates are favorable. The Q&A highlights robust feedback and growth in new applications, enhancing the sentiment. The positive aspects outweigh the lack of long-term guidance, suggesting a potential stock price increase in the short term.
The earnings call highlighted strong financial performance with a 42% sales increase and a 50% growth guidance for 2025. Product innovations and successful reimbursement progress are positive indicators. Despite operating losses, improved EBITDA and cash position provide stability. The Q&A revealed positive market reception for new products and mapping technology, with strategic investments in sales expected to drive growth. However, uncertainties in partnership discussions and unclear timelines for nelitolimod present some risks. Overall, the positive financials, growth trajectory, and market reception outweigh the uncertainties, suggesting a positive stock price movement.
The earnings call revealed mixed signals: strong revenue growth and reduced losses, but ongoing financial challenges and competitive pressures. The Q&A highlighted positive feedback on products and expansion efforts but also showed management's reluctance to provide clear guidance, raising concerns. The private placement and preferred share exchange offer could dilute stock value. Overall, the company's strategic initiatives and product performance are promising, but financial uncertainties and competitive challenges temper the outlook, resulting in a neutral sentiment.
The earnings call presents a generally positive outlook with strong revenue growth and reduced losses. The Q&A section reveals favorable feedback on new products and strategic initiatives, although some management responses lacked clarity. The strategic partnership focus and cash infusion from a private placement support growth prospects. Despite slight gross margin decline, the overall sentiment remains positive, driven by significant revenue growth and operational improvements. The absence of market cap information limits the prediction's precision, but the positive indicators suggest a stock price increase in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
